Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer

BACKGROUND: In cases of EGFR‐tyrosine kinase inhibitor (TKI) failure, re‐biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re‐biopsy is challenging because of several hurdles. We assessed the feasibility of re‐biopsy in advanced non‐s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Thorac Cancer
Auteurs principaux: Kim, Tae‐Ok, Oh, In‐Jae, Kho, Bo Gun, Park, Ha Young, Chang, Jin Sun, Park, Cheol‐Kyu, Shin, Hong‐Joon, Lim, Jung‐Hwan, Kwon, Yong‐Soo, Kim, Yu‐Il, Lim, Sung‐Chul, Kim, Young‐Chul, Choi, Yoo‐Duk
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons Australia, Ltd 2018
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026616/
https://ncbi.nlm.nih.gov/pubmed/29761660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12762
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires